Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

COMPARISON OF MOMETASONE FUROATE 0.1-PERCENT CREAM AND HYDROCORTISONE 1.0-PERCENT CREAM IN THE TREATMENT OF CHILDHOOD ATOPIC-DERMATITIS JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Vernon, H. J., Lane, A. T., Weston, W. 1991; 24 (4): 603-607

Abstract

We conducted a 6-week randomized, blinded study that compared mometasone furoate 0.1% cream, applied once daily, and hydrocortisone 1.0% cream, applied twice daily, in 48 children with moderate to severe atopic dermatitis. Mometasone furoate, a moderate-potency steroid, produced significantly greater improvement than the low-potency hydrocortisone used twice daily. The difference in therapeutic response was particularly evident in patients with involvement of more than 25% of their body surface area. Morning plasma cortisol levels were assayed before treatment, after 1 week of therapy, and at the end of the clinical trial. Plasma cortisol levels were transiently suppressed in one child who was treated with hydrocortisone and in none of the children treated with mometasone.

View details for Web of Science ID A1991FD90300016

View details for PubMedID 2033138